Birgitta Benda

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman et al. · The Lancet · 2013 · 720 citations

Medicine, Pharmacology, Pharmacotherapy +12

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann et al. · Arthritis & Rheumatism · 2013 · 582 citations

Medicine, Internal Medicine, Pharmacotherapy +14

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Lars Erik Kristensen, Silvio Danese, Arne Yndestad et al. · Annals of the Rheumatic Diseases · 2023 · 119 citations · Full text

Public Health, Oncology, Pharmacotherapy +12

XENOGRAFT REJECTION OF PORCINE ISLET-LIKE CELL CLUSTERS IN IMMUNOGLOBULIN- OR Fc-RECEPTOR ??-DEFICIENT MICE1

Birgitta Benda, Alex Karlsson‐Parra, Anna Ridderstad et al. · Transplantation · 1996 · 50 citations

Life Sciences, Cell Biology, Immunology +16

XENOGRAFT REJECTION OF PORCINE ISLET-LIKE CELL CLUSTERS IN NORMAL, INTERFERON-??, AND INTERFERON-?? RECEPTOR DEFICIENT MICE1

Jan-Olov Sandberg, Birgitta Benda, Nils Lycke et al. · Transplantation · 1997 · 31 citations

Life Sciences, Cell Biology, Immunology +15